Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance

Yoshiji,Hitoshi; Noguchi,Ryuichi; Namisaki,Tadashi; Moriya,Kei; Kitade,Mitsuteru; Aihara,Yosuke; Douhara,Akitoshi; Yamao,Junichi; Fujimoto,Masao; Toyohara,Masahisa; Mitoro,Akira; Sawai,Masayoshi; Yoshida,Motoyuki; Morioka,Chie; Uejima,Masakazu; Uemura,Masahito; Fukui,Hiroshi

doi:10.3892/or.2013.2497

Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance

Authors:
- Hitoshi Yoshiji
- Ryuichi Noguchi
- Tadashi Namisaki
- Kei Moriya
- Mitsuteru Kitade
- Yosuke Aihara
- Akitoshi Douhara
- Junichi Yamao
- Masao Fujimoto
- Masahisa Toyohara
- Akira Mitoro
- Masayoshi Sawai
- Motoyuki Yoshida
- Chie Morioka
- Masakazu Uejima
- Masahito Uemura
- Hiroshi Fukui
View Affiliations

Affiliations: Third Department of Internal Medicine, Nara Medical University, Nara, Japan
Published online on: May 27, 2013 https://doi.org/10.3892/or.2013.2497
Pages: 545-552
Copyright: © Yoshiji et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Branched-chain amino acids (BCAAs) reportedly inhibit the incidence of hepatocellular carcinoma (HCC) in patients with liver cirrhosis and obesity that is frequently associated with insulin resistance (IR). We previously reported that BCAAs exert a chemopreventive effect against HCC under IR conditions in rats. The aim of the present study was to examine the effect of BCAAs on the cumulative recurrence of HCC under IR conditions in the clinical practice. BCAA granules (Livact®, 12 g/day) were administered for 60 months following the local curative therapy for HCC, and several indices were determined. Treatment with BCAAs markedly inhibited the cumulative recurrence of HCC in patients with a high IR index [homeostasis model assessment (HOMA)-IR >2.5], but not in patients with HOMA-IR of ≤2.5. BCAA also improved the HOMA-IR, and the inhibitory effect was observed regardless of the serum albumin (Alb) levels. Similarly, BCAA treatment revealed a marked suppressive effect in patients with high fasting insulin [immune reactive insulin (IRI) >15 U/ml], but not with IRI of ≤15. BCAA treatment did not result in differences in HCC recurrence in patients with high and low glucose levels [fasting blood sugar (FBS) >110 and ≤110, respectively]. Furthermore, serum levels of the soluble form of vascular endothelial growth factor receptor 2 (sVEGFR2) were significantly inhibited along with these clinical effects. Our findings indicate that the inhibitory effect of BCAAs was achieved, at least partly, by coordinated effects of anti-angiogenesis and IR improvement. Since BCAAs are widely and safely used in clinical practice to treat patients with chronic liver diseases, BCAAs may represent a new strategy for secondary chemoprevention for HCC patients with IR. Moreover, our findings suggest that sVEGFR2 may be a useful clinical predictive marker for BCAA treatment under IR conditions.

View Figures

View References

1	Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar
2	Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21:505–515. 2000. View Article : Google Scholar : PubMed/NCBI
3	Shojaei F: Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
4	Guo RP, Zhong C, Shi M, et al: Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 132:547–555. 2006. View Article : Google Scholar : PubMed/NCBI
5	Iavarone M, Lampertico P, Iannuzzi F, et al: Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat. 14:133–139. 2007. View Article : Google Scholar : PubMed/NCBI
6	Dufour JF: Anti-angiogenic therapy for HCC. Minerva Gastroenterol Dietol. 58:81–86. 2012.PubMed/NCBI
7	Li CY, Shan S, Huang Q, et al: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 92:143–147. 2000. View Article : Google Scholar
8	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar
9	Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284:808–812. 1999. View Article : Google Scholar : PubMed/NCBI
10	Brandvold KA, Neiman P and Ruddell A: Angiogenesis is an early event in the generation of myc-induced lymphomas. Oncogene. 19:2780–2785. 2000. View Article : Google Scholar : PubMed/NCBI
11	Yoshiji H, Kuriyama S, Yoshii J, et al: Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology. 39:1517–1524. 2004. View Article : Google Scholar
12	Frachon S, Gouysse G, Dumorti J, et al: Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol. 34:850–857. 2001. View Article : Google Scholar : PubMed/NCBI
13	Kahn CR: Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Metabolism. 27:1893–1902. 1978. View Article : Google Scholar : PubMed/NCBI
14	Davila JA, Morgan RO, Shaib Y, McGlynn KA and El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 54:533–539. 2005. View Article : Google Scholar : PubMed/NCBI
15	El-Serag HB, Tran T and Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 126:460–468. 2004. View Article : Google Scholar : PubMed/NCBI
16	Shintani Y, Fujie H, Miyoshi H, et al: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 126:840–848. 2004. View Article : Google Scholar : PubMed/NCBI
17	Habu D, Shiomi S, Tamori A, et al: Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA. 292:358–361. 2004. View Article : Google Scholar : PubMed/NCBI
18	Bugianesi E, McCullough AJ and Marchesini G: Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 42:987–1000. 2005. View Article : Google Scholar : PubMed/NCBI
19	Marchesini G, Bianchi G, Merli M, et al: Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 124:1792–1801. 2003. View Article : Google Scholar : PubMed/NCBI
20	Muto Y, Sato S, Watanabe A, et al: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 3:705–713. 2005. View Article : Google Scholar : PubMed/NCBI
21	Muto Y, Sato S, Watanabe A, et al: Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 35:204–214. 2006.PubMed/NCBI
22	Nishitani S, Ijichi C, Takehana K, Fujitani S and Sonaka I: Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. Biochem Biophys Res Commun. 313:387–389. 2004. View Article : Google Scholar : PubMed/NCBI
23	Nishitani S, Takehana K, Fujitani S and Sonaka I: Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 288:G1292–G1300. 2005. View Article : Google Scholar : PubMed/NCBI
24	Kawaguchi T, Taniguchi E, Itou M, et al: Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases. Liver Int. 27:1287–1292. 2007.PubMed/NCBI
25	Kawaguchi T, Nagao Y, Matsuoka H, Ide T and Sata M: Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med. 22:105–112. 2008.PubMed/NCBI
26	Kaji K, Yoshiji H, Kitade M, et al: Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med. 22:801–808. 2008.PubMed/NCBI
27	Yoshiji H, Noguchi R, Kitade M, et al: Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol. 44:483–491. 2009. View Article : Google Scholar : PubMed/NCBI
28	Tsuchiya K, Asahina Y, Sato T, et al: Oral supplementation with branched-chain amino acid (BCAA) improves survival and decreases the third time recurrence after successful treatment of hepatocellular carcinoma (HCC). J Hepatol (EASL proceeding). (48 suppl)2:S1602009.
29	Yoshiji H, Noguchi R, Toyohara M, et al: Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol. 51:315–321. 2009. View Article : Google Scholar
30	Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar
31	Bruix J and Sherman M: Diagnosis of small HCC. Gastroenterology. 129:13642005. View Article : Google Scholar : PubMed/NCBI
32	Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R and Serfaty L: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 54:1003–1008. 2005. View Article : Google Scholar : PubMed/NCBI
33	Ferrara N: VEGF as a therapeutic target in cancer. Oncology. 69:11–16. 2005. View Article : Google Scholar
34	Yoshiji H, Noguchi R, Ikenaka Y, et al: Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep. 26:1547–1553. 2011.
35	Kaji K, Yoshiji H, Ikenaka Y, et al: Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. Curr Med Chem. 19:1889–1898. 2012. View Article : Google Scholar
36	Hagiwara A, Nishiyama M and Ishizaki S: Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J Cell Physiol. 227:2097–2105. 2012. View Article : Google Scholar
37	Kawaguchi T, Izumi N, Charlton MR and Sata M: Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 54:1063–1070. 2011. View Article : Google Scholar : PubMed/NCBI
38	Shimizu M, Kubota M, Tanaka T and Moriwaki H: Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci. 13:579–595. 2012. View Article : Google Scholar : PubMed/NCBI
39	Yoshiji H, Noguchi R, Kaji K, et al: Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol. 45:443–450. 2010. View Article : Google Scholar
40	Miuma S, Ichikawa T, Arima K, et al: Branched-chain amino acid deficiency stabilizes insulin-induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells. J Cell Biochem. 113:3113–3121. 2012. View Article : Google Scholar
41	Yoshiji H, Kuriyama S, Yoshii J, et al: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology. 35:834–842. 2002. View Article : Google Scholar : PubMed/NCBI
42	Wierzbowska A, Robak T, Wrzesień-Kuś A, Krawczyńska A, Lech-Marańda E and Urbańska-Ryś H: Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw. 14:149–153. 2003.PubMed/NCBI
43	Deprimo SE, Bello CL, Smeraglia J, et al: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 5:322007. View Article : Google Scholar : PubMed/NCBI
44	Nagaoka S, Yoshida T, Akiyoshi J, et al: The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep. 23:1647–1654. 2010.